The "Psoriatic Arthritis: Epidemiology Forecast to 2033" report has been added to ResearchAndMarkets.com's offering. This report provides an overview of the risk factors, comorbidities, and global and ...

For patients with psoriatic arthritis, switching directly from adalimumab to tofacitinib with no washout period presents no ...

Researchers identified 3 distinct PsA phenotype clusters, emphasizing the importance of PsO severity in treatment decision making.

Bimekizumab (Bimzelx; UCB Pharma) was approved by the FDA to treat psoriatic arthritis (PsA) on September 23, 2024, based on ...

Topline data were announced from two phase 3 trials evaluating deucravacitinib in adults with active psoriatic arthritis.

Misuse of screening tools and subsequent underdiagnosis of the condition can easily occur, even amongst specialists.

Can a protein involved in delivering Vitamin D to target tissues have an altered serum profile in psoriasis patients with ...

In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...

Stull said that a number of prescription treatments exist for topical psoriasis, such as steroids and injectable therapies, ...

The Biden administration says popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of ...